RecruitingNot Applicable

A Qualitative Assessment of the Severity and Impact of Rheumatic Immune-Related Adverse Events Following Immune Checkpoint Inhibitor Immunotherapy

United States20 participantsStarted 2024-09-11

Plain-language summary

To understand the severity and nature of participants experiences during irAEs following immune checkpoint inhibitor immunotherapy.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria The criteria are: * Patients aged 18 years and above * English (conversational level) speaking, with the ability to give informed consent * Patients with a rheumatologist clinician diagnosis of inflammatory arthritis irAE or PMR irAE following ICI therapy Exclusion Criteria * Acutely life-threatening or worsening cancer * Hearing impairment functionally limiting participation in verbal interview

What they're measuring

Safety and Adverse Events (AEs).

Timeframe: Through study completion; an average of 1 year

Trial details

NCT IDNCT06647134

SponsorM.D. Anderson Cancer Center

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2028-03-31

Contact for this trial

Y. Jeff Li, MD

713-409-1565 yli61@mdanderson.org

View on ClinicalTrials.gov More Arthritis trials